DiagnoCure's Q1 Revenues Jump 90 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DiagnoCure today reported a 90 percent increase year over year in revenues for its fiscal first quarter of 2012.

For the period ended Jan. 31, revenues totaled C$556,158, (US$557,400) compared to C$292,878 a year ago. During the quarter, the Quebec City-based firm received C$268,567 from Signal Genetics for R&D services provided related to the Previstage GCC Colorectal Cancer Staging Test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."